Perinatal Asphyxia Clinical Trial
Official title:
A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) in Neonates With ≥36 Weeks GA With Moderate to Severe Perinatal Asphyxia
In case of insufficient oxygen supply to the brain of a newborn child (perinatal asphyxia),
toxic compounds will be formed. These toxic compounds will damage the cells of the brain. 2
Iminobiotin (2 IB) is an investigational medicinal product that is related to vitamin B7.
From studies in animals it has been shown that 2-IB may prevent the formation of the toxic
compounds. Also it has been shown to be safe in in studies in juvenile animals and in
healthy, adult male volunteers. The doctors hope that this will prevent (part of) the
potential brain damage that may result from lack of oxygen to the brain.
This study is the first study in the target population: newborn with moderate to severe
oxygen shortage during birth. In this study the investigators evaluate short term efficacy,
safety and pharmacokinetics of 2-Iminobiotin. In the follow-up phase the investigators
evaluate the long term efficacy and safety.
The study hypothesis is that 2-Iminobiotin will help to decrease the brain damage after
oxygen shortage and is indeed safe. The brain damage will be measured both in the first week
and during the first two years of life. The study was designed as a study with two parts an
open label pilot part (6 patients) and a double-blind randomised part (60 patients). Due to
lack of recruitment it was decided in September2014 to stop recruitment after the open label
pilot part of the study (6 patients).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06322732 -
Optimization of Routine Obstetric and Neonatal Care in the Management of Severe Perinatal Asphyxia in Term or Near-term Newborns: Analysis of Sub-optimal Care
|
||
Completed |
NCT05687708 -
Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia
|
N/A | |
Completed |
NCT00062452 -
Esophageal Motility and Airway Defenses Among Infants
|
N/A | |
Completed |
NCT05946681 -
Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings
|
||
Completed |
NCT02002039 -
Neuroprotective Role of Erythropoietin in Perinatal Asphyxia
|
Phase 2/Phase 3 | |
Completed |
NCT04820504 -
Augmented Infant Resuscitator to Enhance Newborn Ventilation
|
N/A | |
Completed |
NCT02071160 -
Melatonin for Neuroprotection Following Perinatal Asphyxia
|
Phase 1/Phase 2 | |
Recruiting |
NCT06090968 -
Umbilical Cord Milking Versus Immediate Cord Clamping in Full Term Neonates (≥ 37 Weeks) Requiring Resuscitation
|
N/A | |
Completed |
NCT03854435 -
Determination of Heart Rate in Infants Needing Resuscitation at Birth
|
N/A | |
Completed |
NCT02700854 -
Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2
|
Phase 1 | |
Active, not recruiting |
NCT05349175 -
Augmented Infant Resuscitator (AIR): Transitioning a Novel Behavior Change Innovation to Drive Newborn Ventilation Skills Enhancement
|
N/A | |
Completed |
NCT03968861 -
Outcome After 24 Months of Participants in the TOBY Xenon Study
|
||
Recruiting |
NCT05574855 -
Evaluation of Haemodynamic in Neonates Treated With Hypothermia"
|
||
Completed |
NCT00624871 -
Ascorbic Acid and Ibuprofen in Infants With Hypoxic Ischemic Encephalopathy
|
N/A |